Silence Therapeutics Plc (SLN) Investor Relations Documents

Silence Therapeutics Plc (SLN) investor relations documents from the company's IR site: 13 presentations, 8 press releases; latest deck 2026-08-10. Read in-app with summaries. First-party data.

SANRECO Phase 2 Topline Results Webcast: Silence Therapeutics reports positive Phase 2 SANRECO topline results for divesiran in polycythemia vera, meeting the primary endpoint with 88% responder rate.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-10Earnings deckSANRECO Phase 2 Topline Results Webcast
2026-08-10Press releasePress Release
2026-06-11Press releaseSilence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Pr
2026-05-27Press releaseSilence Therapeutics to Participate in Jefferies Global Healthcare Conference
2026-05-12Press releaseSilence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
2026-05-07Press releasePress Release
2026-05-04Annual reportUK Annual Report
2026-03-05Press releaseSilence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Res
2025-06-12PresentationSANRECO, an On-going Phase 1/2 Study Evaluating Divesiran, a Novel GalNAc-conjugated SiRNA, in Patients with Polycythemi
2025-04-29Annual reportUK Annual Report
2025-02-27PresentationPresentation
2024-12-08PresentationInitial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel GalNAc Conjugated siRNA, in Patients with Polycythe
2024-06-27PresentationSilence Therapeutics Conference Call to Discuss SANRECO Phase 1 Results
2024-03-13Earnings deckPresentation
2023-03-15PresentationPresentation
2022-06-01PresentationPLATFORM TECHNOLOGY – Confident Silence: Delivering on the Promise of siRNA Therapies
2022-03-16PresentationPresentation
2021-11-10Regulatory reportSilence Therapeutics - Holding(s) in Company
2021-10-28Regulatory reportSilence Therapeutics - Holding(s) in Company
2021-10-15Press releasehere
2021-10-08Regulatory reportSilence Therapeutics - Block Listing Return
2021-09-08Regulatory reportSilence Therapeutics - Holding(s) in Company
2021-09-08Regulatory reportSilence Therapeutics - Holding(s) in Company
2021-08-12PresentationPresentation
2021-05-19PresentationRBC Capital Markets Global Healthcare Conference
2021-05-12Press releaseSilence Therapeutics - Silence attends RBC Global Healthcare Conference
2021-04-29Regulatory reportSilence Therapeutics - Holding(s) in Company
2021-03-30Earnings deckPresentation
2021-02-24Regulatory reportSilence Therapeutics - Holding(s) in Company
2021-02-15Regulatory reportSilence Therapeutics - Holding(s) in Company
2021-02-15Regulatory reportSilence Therapeutics - Holding(s) in Company
2021-02-12Regulatory reportSilence Therapeutics - Holding(s) in Company
2021-02-12Regulatory reportSilence Therapeutics - Holding(s) in Company
2021-02-11Regulatory reportSilence Therapeutics - Holding(s) in Company
2021-01-06Regulatory reportSilence Therapeutics - Holdings in Company
2020-12-29Regulatory reportSilence Therapeutics - Holdings in Company
2020-12-14Regulatory reportSilence Therapeutics - Holding(s) in Company
2020-09-14PresentationPresentation
2020-09-04Regulatory reportHolding(s) in Company
2020-07-22Regulatory reportHolding(s) in Company

SLN overview · SLN earnings · SLN financials · SLN KPIs · SLN documents · SLN ownership · SLN peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.